Anzor Pharmaceuticals Announces Groundbreaking Patent for Novel α-Klotho Protein Therapy
Innovative Modified Soluble α-Klotho Protein Shows Promise for Treating the $16B Chronic Kidney Disease and Phosphate Metabolism Disorders Markets Boston, AM – October 14, 2025 – Anzor Pharmaceuticals is pleased to announce the issuance of U.S. Patent No. 12,227,777 B2 for a novel modified soluble α-Klotho protein with enhanced therapeutic properties. This breakthrough technology represents […]
Anzor Pharmaceuticals to Present at Chronic Kidney Disease Conference
FGF TECHNOLOGY REPRESENTS MAJOR BREAKTHROUGH IN METABOLIC AND CANCER DISEASES BOSTON, March 19, 2025 – Anzor Pharmaceuticals, a leader in the development of targeted fibroblast growth factor (FGF) peptide therapy, today announced that Christopher P Adams, CEO will present at the 7th Annual Chronic Kidney Disease Conference in Boston Massachusetts on March 19, 2025. […]
